Free Trial
NASDAQ:NAGE

Niagen Bioscience (NAGE) Stock Price, News & Analysis

Niagen Bioscience logo
$2.02 -0.06 (-2.66%)
As of 03:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Niagen Bioscience Stock (NASDAQ:NAGE)

Advanced

Key Stats

Today's Range
$1.97
▼
$2.06
50-Day Range
$2.07
▼
$3.17
52-Week Range
$1.97
▼
$7.11
Volume
664,702 shs
Average Volume
829,704 shs
Market Capitalization
$159.59 million
P/E Ratio
16.79
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses.

The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025.

Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels. Rob Fried is the company’s chief executive officer.

AI Generated. May Contain Errors.

Niagen Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

NAGE MarketRank™: 
2.886119581065 of 5 stars

Niagen Bioscience scored higher than 58% of companies evaluated by MarketBeat, and ranked 90th out of 168 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Niagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Niagen Bioscience has a consensus price target of $8.50, representing about 328.2% upside from its current price of $1.99.

  • Amount of Analyst Coverage

    Niagen Bioscience has only been the subject of 3 research reports in the past 90 days.

  • Read more about Niagen Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Niagen Bioscience are expected to decrease by -25.00% in the coming year, from $0.04 to $0.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Niagen Bioscience is 16.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.15.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Niagen Bioscience is 16.54, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 25.86.

  • Price to Book Value per Share Ratio

    Niagen Bioscience has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.10% of the float of Niagen Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Niagen Bioscience has a short interest ratio ("days to cover") of 8.91.
  • Change versus previous month

    Short interest in Niagen Bioscience has recently increased by 4.16%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Niagen Bioscience does not currently pay a dividend.

  • Dividend Growth

    Niagen Bioscience does not have a long track record of dividend growth.

  • News Sentiment

    Niagen Bioscience has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Niagen Bioscience this week, compared to 4 articles on an average week.
  • Search Interest

    3 people have searched for NAGE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Niagen Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.00% of the stock of Niagen Bioscience is held by insiders.

  • Percentage Held by Institutions

    15.41% of the stock of Niagen Bioscience is held by institutions.

  • Read more about Niagen Bioscience's insider trading history.
Receive NAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NAGE Stock News Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Headlines

NAGE Stock Analysis - Frequently Asked Questions

Niagen Bioscience's stock was trading at $6.36 at the beginning of 2026. Since then, NAGE shares have decreased by 68.8% and is now trading at $1.9850.

Niagen Bioscience, Inc. (NASDAQ:NAGE) announced its earnings results on Wednesday, November, 4th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The firm had revenue of $27.19 million for the quarter. Niagen Bioscience had a net margin of 8.37% and a trailing twelve-month return on equity of 10.18%.

Niagen Bioscience's top institutional investors include SteelPeak Wealth LLC (4.49%), State Street Corp (1.37%), Marshall Wace LLP (0.59%) and Russell Investments Group Ltd. (0.10%). Insiders that own company stock include Frank L Jaksch Jr, Brianna Gerber, Ozan Pamir and Kristin Patrick.
View institutional ownership trends
.

Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Niagen Bioscience investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Micron Technology (MU), Novavax (NVAX) and Broadcom (AVGO).

Company Calendar

Last Earnings
11/04/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Personal Care Products
Sub-Industry
Personal Care Products
Current Symbol
NASDAQ:NAGE
Previous Symbol
NASDAQ:NAGE
CIK
1386570
Employees
117
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$6.00
Potential Upside/Downside
+319.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.12
Trailing P/E Ratio
16.88
Forward P/E Ratio
67.50
P/E Growth
N/A
Net Income
$17.38 million
Net Margins
8.37%
Pretax Margin
9.04%
Return on Equity
10.18%
Return on Assets
7.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.93
Quick Ratio
4.71

Sales & Book Value

Annual Sales
$129.42 million
Price / Sales
1.24
Cash Flow
$0.20 per share
Price / Cash Flow
10.18
Book Value
$0.96 per share
Price / Book
2.11

Miscellaneous

Outstanding Shares
79,200,000
Free Float
71,277,000
Market Cap
$160.38 million
Optionable
Optionable
Beta
2.12
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:NAGE) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners